Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Dexamethasone
Drug: Bortezomib
First Posted Date
2008-07-21
Last Posted Date
2013-10-29
Lead Sponsor
Janssen-Ortho Inc., Canada
Target Recruit Count
10
Registration Number
NCT00718640

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

First Posted Date
2008-07-14
Last Posted Date
2019-06-24
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
6
Registration Number
NCT00714246
Locations
🇺🇸

Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

First Posted Date
2008-07-09
Last Posted Date
2019-04-16
Lead Sponsor
Mayo Clinic
Target Recruit Count
21
Registration Number
NCT00711828
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

First Posted Date
2008-07-02
Last Posted Date
2020-12-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
29
Registration Number
NCT00708292
Locations
🇺🇸

Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale, Arizona, United States

🇺🇸

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio, Texas, United States

🇪🇸

Novartis Investigative Site, Madrid, Spain

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2008-06-23
Last Posted Date
2018-08-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT00703664
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

and more 9 locations

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

First Posted Date
2008-06-23
Last Posted Date
2014-11-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT00703300
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1
Terminated
Conditions
714leukemia
Lymphoma
Interventions
Drug: Bortezomib
Drug: Everolimus
First Posted Date
2008-05-05
Last Posted Date
2015-10-28
Lead Sponsor
Brian Hill, MD, PhD
Target Recruit Count
30
Registration Number
NCT00671112
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

First Posted Date
2008-05-01
Last Posted Date
2018-08-16
Lead Sponsor
Jennifer E. Schwartz
Target Recruit Count
27
Registration Number
NCT00670423
Locations
🇺🇸

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

First Posted Date
2008-04-28
Last Posted Date
2011-05-10
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
16
Registration Number
NCT00667641
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

First Posted Date
2008-04-25
Last Posted Date
2018-05-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
52
Registration Number
NCT00666588
Locations
🇺🇸

Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 79 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy